On August 14, 2026, at the preliminary round of the 10th “Red Boat Cup” Jiaxing Global Entrepreneurship Competition – Life & Health Track, Dr. Weijie Chen, Chairman of Lishan Biotech, presented the “Live Biologic Drug LBP Project for Intestinal Microbiota”. Standing out among 20 cutting‑edge innovation projects for its outstanding originality and industrialization potential, the project was awarded the First Prize and successfully qualified for the Grand Final.

Hosted by Zhejiang Tsinghua Yangtze River Delta Research Institute, the competition adopts the theme “Grow with You, Innovate for the Future”. It focuses on four strategic sectors: life and health, intelligent equipment, new energy and new materials, as well as embodied intelligence, and solicits high‑caliber entrepreneurial projects worldwide. There are seven tracks in the preliminary round, and a total of 21 projects — the top three from each track — have advanced to the Grand Final to be held in Jiaxing in September.

This award represents high recognition from the competition organizing committee for Dr. Chen Weijie’s team and its strengths in “AI‑empowered live biologic drug R&D and clinical patient enrollment”. It also reflects the industry’s firm confidence in the broad prospects of microbiome therapeutics. We look forward to Dr. Chen building on this momentum and achieving further excellent results in the Grand Final.

About Lishan Biotech

Lishan Biotech is a biopharmaceutical enterprise focusing on AI‑driven R&D and clinical enrollment for live biologic drugs. Leveraging its proprietary bacterial swarming technology, together with the intelligently deployed Intelligent Microbiome Application Platform (IMicAP) and Microbiome Intervention Differential Analysis System (MiDAS), the Company has built a one‑stop solution spanning from research support to translational development. This solution covers core modules including microbiome mining, process development, functional evaluation, safety assessment and clinical translation support, and delivers systematic R&D technical services for enterprises, universities and hospitals.

From fundamental research to deciphering mechanisms behind gut microbiota, to noise‑reduced, truth‑oriented, data‑driven precision insights, Lishan Biotech applies its unique paradigm of “AI reshaping live biologic drug R&D”. The enterprise is advancing from technological accumulation toward industrial leadership, striving to become a globally competitive innovative platform company in the field of microbiome therapeutics.